ASPI Merger Partner ENDRA Files S-4 Registration Statement for Proposed Transaction

ASP Isotopes Inc. (ASPI) provided an update on its previously announced merger agreement, noting that its partner, ENDRA Life Sciences Inc., has filed a Registration Statement on Form S-4 with the SEC. This filing is a key step in the proposed merger transaction involving ASPI's subsidiaries, Noble Africa LLC and Renergen Limited.

Key Details

• Regulatory Filing: ENDRA Life Sciences Inc. filed the Registration Statement on Form S-4 on October 2, 2026, which contains important information regarding the proposed merger.
• Transaction Background: The filing relates to the Merger Agreement dated June 25, 2026, under which a subsidiary of ENDRA will merge with ASPI's subsidiary, Noble Africa LLC.
• Post-Merger Structure: Upon completion, Noble Africa will survive the merger and become a direct, wholly-owned subsidiary of ENDRA.